Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
EPRX
EPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EPRX News
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
Mar 17 2026
stocktwits
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
Mar 13 2026
seekingalpha
Eupraxia Completes Public Offering of 7.6 Million Shares
Feb 20 2026
Newsfilter
Eupraxia Pharmaceuticals Prices Public Offering
Feb 19 2026
seekingalpha
Eupraxia Pharmaceuticals Prices $55 Million Public Offering
Feb 19 2026
NASDAQ.COM
Eupraxia Pharmaceuticals Prices Public Offering at $7.00 per Share
Feb 19 2026
Newsfilter
Eupraxia Pharmaceuticals Proposes Public Offering of Common Shares
Feb 18 2026
seekingalpha
Eupraxia Pharmaceuticals Reports Significant Tissue Health Improvements in EoE Trial
Jan 08 2026
Benzinga
Eupraxia Pharmaceuticals Reports Positive 12-Week and 36-Week Data for EP-104GI in EoE Treatment
Jan 08 2026
NASDAQ.COM
Eupraxia Pharmaceuticals Shares New 52-Week Follow-Up Data from the RESOLVE Trial on Eosinophilic Esophagitis (EoE) Showing Consistent Outcomes with EP-104GI Treatment
Nov 13 2025
Newsfilter
Peterson Capital Organizes Canada Growth Conference in Ireland
Sep 25 2025
Newsfilter
Eupraxia Pharmaceuticals Completes $80.5 Million Public Offering with Full Underwriter Option Exercised
Sep 24 2025
Newsfilter
Eupraxia Pharmaceuticals sets share offering at $70 million
Sep 23 2025
SeekingAlpha
HC Wainwright & Co. Affirms Buy Rating for Eupraxia Pharmaceuticals, Keeps $12 Price Target Intact
Aug 20 2025
Benzinga
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 12 2025
Newsfilter
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Jul 24 2025
Benzinga
Show More News
